October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Study: Long working hours alter brain regions tied to emotion, cognition
- Survey: Burnout, rigid schedules push nurses to leave
- UCLA surgeons perform world’s first bladder transplant
- AHA urges HHS to cut regulations that burden hospitals and staff
- Commentary: Overlooking, underfunding perioperative mental health threatens patients
- Study: Fewer men undergo unnecessary prostate cancer surgery amid rise in active surveillance
- OpenAI benchmarking tool tests healthcare LLMs
- Healthgrades recognizes top 15% of hospitals for patient experience in 2025
- Q1 reports show climb in outpatient surgical volume, diverging trends at Surgery Partners, Ardent Health
- Study: SGLT2 inhibitors raise postop euglycemic ketoacidosis risk but lower mortality
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement